If a deal is struck, a Roche-Ventana team could help launch the expected medical revolution - personalized medicine.
In the coming decade, pharmaceutical products--especially cancer drugs--will be created in tandem with diagnostic tests that tell doctors which patients are likely to benefit. Right now, physicians often feel they're flying blind. Each patient arrives at the hospital with a unique genetic makeup, which affects whether a prescribed drug will kill tumor cells, cause devastating side effects, or possibly do nothing at all. If a new generation of gene tests can help predict these different outcomes, patients will be spared expensive and unhelpful ordeals. The pool of target patients for many medications will also shrink. But if doctors are confident a drug will help somebody, they'll prescribe it aggressively, and insurers will be more likely to foot the bill.
A Dream Team Of Drugs And Diagnosis? Business Week.
- ► 2013 (23)
- ► 2008 (24)
- MicroRNAs may be key to HIV's ability to hide, eva...
- Is DCA "The Cure" for Cancer?
- BIRD FLU IN SASKATCHEWAN CANADA
- Researchers develop new technique to synthesize dr...
- DNA unraveled - New info Francis Collin's calls a ...
- A Dream Team Of Drugs And Diagnosis?
- Senate OKs FDA drug safety bill and Pharma has to...
- Genome Area Linked to Rheumatoid Arthritis
- Will Sharing Ideas Advance Cancer Research?
- Genetics Hold Promise, Challenges for Cancer Care
- ▼ September (10)
- ► 2006 (77)